MODERNA WINS REUTERS PHARMA AWARDS FOR DELIVERING INCLUSIVE TRIALS

MODERNA WINS REUTERS PHARMA AWARDS FOR DELIVERING INCLUSIVE TRIALS

Honour is regarded for delivering clinical trials that excel in enabling diverse patient recruitment and retention, impacting underrepresented demographics.

LONDON, UK / NOVEMBER 18, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, yesterday announced that they have won The Delivering Inclusive Trials Award at the Reuters Pharma Europe 2022. The announcement came during the Award Ceremony on Thursday, 17 November at Northumberland Avenue in London, which recognises Moderna’s dedication to advancing trials that reflect the diversity in our communities.

“Everyone, regardless of their backgrounds, should have an opportunity to be a part of world-class medical research. This award is a huge honour, thank you to the Moderna team for their efforts.” – said Jameka Hill, Director, Patient Engagement and Advocacy, Diversity and Inclusion Lead, Moderna.

COVID-19 has a disproportionate impact on racial and ethnic minority communities. Ultimately the COVE trial included more than 11,000 participants from communities of colour, representing 37% of the study population, which was similar to the diversity of the U.S. at large and representative of the U.S. population at risk for COVID-19 infection.

Moderna have invested in a talented team that is deeply committed to inclusivity at all stages of research and development and includes a Diversity & Inclusion lead who sits within Moderna’s clinical development teams. Moderna have also incorporated the COVE trial learnings (such as demographic enrollment goals) into other non-COVID studies and will continue to do so. While there is no “one size fits all” method to fostering inclusion, Moderna believes that the systems and methods we have established within the company will serve our communities well for years to come.

The Reuters Pharma Awards programme is dedicated to celebrating the industry’s honourable work to improve patient outcomes, create value for customers and address long-lasting health inequities.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programmes in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com/en-GB.

Moderna Contacts

Media:

Emma Gilgunn-Jones

Director, Communications and Digital Media, Moderna

media@modernatx.com